Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | F3 | P13726 | 2/20 | 1.00 |
| ▸ | MGAM | O43451 | 3/20 | 0.79 |
| ▸ | GAA | P10253 | 3/20 | 0.79 |
| ▸ | SI | P14410 | 3/20 | 0.79 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.79 |
| ▸ | HTT | P42858 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | MIF | P14174 | 1/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Dibenzylidenecyclohexanone SCHEMBL12948726 | 1.00 | CYP1A2 (1.00) | CYP1A2F3MGAMGAASI | |
| 2,6-Dibenzylidenecyclohexanone SCHEMBL977261 | 1.00 | CYP1A2 (1.00) | CYP1A2F3MGAMGAASI | |
| 2,6-Dibenzylidenecyclohexanone SCHEMBL11732505 | 0.98 | CYP1A2 (0.96) | CYP1A2F3MGAMGAASI | |
| 2,6-Dibenzylidenecyclohexanone SCHEMBL11732500 | 0.98 | CYP1A2 (0.96) | CYP1A2F3MGAMGAASI | |
| SCHEMBL3263383 | 0.96 | CYP1A2 (0.92) | CYP1A2F3MGAMGAASI | |
| SCHEMBL3263387 | 0.96 | CYP1A2 (0.92) | CYP1A2F3MGAMGAASI | |
| SCHEMBL11789316 | 0.94 | CYP1A2 (0.88) | CYP1A2F3MGAMGAASI | |
| SCHEMBL11789309 | 0.94 | CYP1A2 (0.88) | CYP1A2F3MGAMGAASI | |
| 2,6-Dibenzylidenecyclohexanone SCHEMBL5688633 | 0.92 | CYP1A2 (0.85) | CYP1A2F3MGAMGAASI | |
| SCHEMBL23633272 | 0.91 | CYP1A2 (1.00) | CYP1A2F3MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5972562-A | Visible radiation-curable solder resist compositions, and method for forming solder resist patterns | FUJITSU LIMITED (JP) | 1999-10-26 | — | — | US | claimed |
| US-20160311386-A1 | ELEMENT OF AN ENGINE COMPARTMENT OF A MOTOR VEHICLE AND METHOD OF PROTECTING THE ELEMENT AGAINST CHEMICAL ATTACKS FROM A METAL HALIDE | HUTCHINSON (FR) | 2016-10-27 | — | — | US | disclosed |
| EP-3083245-A1 | ELEMENT OF AN ENGINE COMPARTMENT OF A MOTOR VEHICLE AND METHOD OF PROTECTING THE ELEMENT AGAINST CHEMICAL ATTACKS FROM A METAL HALIDE | Hutchinson (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC UNM (US) | 2016-02-11 | — | — | US | disclosed |
| US-9204652-B2 | Antibacterial agent, substrate surface treatment method using the same, antibacterial agent composition, and substrate surface treatment method using the same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9187397-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2015092158-A1 | ELEMENT OF AN ENGINE COMPARTMENT OF A MOTOR VEHICLE AND METHOD OF PROTECTING THE ELEMENT AGAINST CHEMICAL ATTACKS FROM A METAL HALIDE | HUTCHINSON (FR) | 2015-06-25 | — | — | WO | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2622960-A1 | ANTIBACTERIAL AGENT, SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME, ANTIBACTERIAL AGENT COMPOSITION, AND SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME | Central Glass Company, Limited (JP) | 2013-08-07 | — | — | EP | disclosed |
| EP-1242352-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | BOWEN, J. PHILLIP | 2002-04-04 | — | — | US | disclosed |
| WO-2001046110-A2 | CHALCONE AND ITS ANALOGS AS AGENTS FOR THE INHIBITION OF ANGIOGENESIS AND RELATED DISEASE STATES | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| US-5972562-A | Visible radiation-curable solder resist compositions, and method for forming solder resist patterns | FUJITSU LIMITED (JP) | 1999-10-26 | — | — | US | disclosed |
| US-5489623-A | APPLYING POLYMER TO SURFACE, EXPOSING TO INCIDENT PHOTONICRADIATION TO RENDER PORTIONS LESS SOLUBLE OR DISPERSIBLE | THE DOW CHEMICAL COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| EP-0676062-A1 | PHOTODEFINABLE POLYMERS CONTAINING PERFLUOROCYCLOBUTANE GROUPS | THE DOW CHEMICAL COMPANY (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5426164-A | Solvent and chemical resistant coatings and photoresists; photocuring of perfluorovinyl polymers containing photo active sites; cyclization | THE DOW CHEMICAL COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1994015258-A1 | PHOTODEFINABLE POLYMERS CONTAINING PERFLUOROCYCLOBUTANE GROUPS | THE DOW CHEMICAL COMPANY (US) | 1994-07-07 | — | — | WO | disclosed |
| US-4004007-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-01-18 | — | — | US | disclosed |
| US-3957762-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040029-A1 | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states | FLT1, FLT4, VEGFA | CYP1A2 795/4885F3 739/4885MGAM 1552/4885 |
| US-20160039734-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | CYP1A2 2544/4885F3 4781/4885MGAM 4452/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | CYP1A2 2544/4885F3 4781/4885MGAM 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.